Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.53 Insider Own33.30% Shs Outstand27.70M Perf Week-6.59%
Market Cap222.83M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float19.40M Perf Month92.46%
Income-14.53M PEG- EPS next Q- Inst Own63.70% Short Float0.66% Perf Quarter190.15%
Sales0.00M P/S- EPS this Y- Inst Trans-1.55% Short Ratio0.15 Perf Half Y201.57%
Book/sh3.84 P/B2.00 EPS next Y- ROA-12.55% Short Interest0.13M Perf Year164.14%
Cash/sh3.61 P/C2.12 EPS next 5Y- ROE-13.01% 52W Range2.34 - 11.55 Perf YTD183.70%
Dividend Est.- P/FCF- EPS past 5Y-46.72% ROI-13.65% 52W High-33.68% Beta-0.32
Dividend TTM- Quick Ratio36.70 Sales past 5Y0.00% Gross Margin- 52W Low227.35% ATR (14)0.92
Dividend Ex-Date- Current Ratio36.70 EPS Y/Y TTM74.06% Oper. Margin0.00% RSI (14)55.38 Volatility9.05% 17.81%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price24.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q92.70% Payout- Rel Volume0.10 Prev Close7.41
Sales Surprise- EPS Surprise-236.00% Sales Q/Q- Earnings- Avg Volume877.26K Price7.66
SMA20-6.35% SMA5046.01% SMA200131.42% Trades Volume86,516 Change3.37%
May-15-24 01:53PM
Apr-11-24 02:42PM
Apr-05-24 06:53AM
Jul-21-23 07:17AM
06:45AM Loading…
Jul-20-23 06:45AM
May-11-23 04:10PM
Apr-21-23 12:00PM
Mar-06-23 04:10PM
Feb-23-23 12:38AM
Feb-10-23 09:31AM
Feb-09-23 04:01PM
Nov-30-22 07:00AM
Nov-14-22 06:10AM
08:47AM Loading…
Nov-12-22 08:47AM
Nov-08-22 07:00AM
Oct-05-22 11:20AM
Aug-15-22 06:10AM
Aug-02-22 09:33AM
Jul-18-22 09:20AM
Jul-07-22 07:00AM
Jun-27-22 04:01PM
May-16-22 06:10AM
May-10-22 10:45AM
May-09-22 09:55AM
07:00AM Loading…
Apr-25-22 07:00AM
Apr-05-22 07:00AM
Mar-21-22 07:00AM
Mar-07-22 04:10PM
Feb-11-22 07:00AM
Feb-07-22 07:00AM
Jan-18-22 07:00AM
Nov-25-21 07:35AM
Nov-08-21 04:01PM
Nov-04-21 07:00AM
Oct-04-21 10:54AM
Sep-13-21 04:10PM
Aug-16-21 10:22AM
Aug-12-21 09:06PM
Aug-09-21 10:33PM
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morisset ValerieEVP, R&D AND CSOApr 05 '24Option Exercise0.0017,8474505,307Apr 08 05:33 PM
Morisset ValerieEVP, R&D AND CSOSep 20 '23Option Exercise0.0020,72814487,460Mar 04 11:07 AM